Al Harthy M, et al. - Researchers reported outcomes of a pooled analysis of phase 1 and randomized phase 2 study which assessed cabozantinib (C) in combination with docetaxel (D) and prednisone (P) (C+DP) to DP alone in patients with mCRPC. They found that 40 mg daily was the highest tolerated dose of C+DP in the phase 1 study. Patients having mCRPC without prior chemotherapy in the castrate setting were considered eligible. A fixed dose of D (75 mg/m²IV day one of each 21 day cycle) and P (5 mg PO twice daily) was administered to all patients. In the C+DP group, C was given at three escalating dose levels: 20 mg, 40 mg, or 60 mg in the phase 1 cohort (all PO daily) and 40 mg daily in the phase 2 cohort. C+DP was used to treat overall 32 patients (19 pts in phase 1 and 13 pts in the phase 2 cohort). Higher PFS and PSA responses were observed in association with C+DP vs DP alone in patients with mCRPC. Also, C+DP was associated with manageable toxicities. Neutropenia (28%), leukopenia (6%), pulmonary embolism (3%), and mucositis (3%) in the C+DP group and hyperglycemia (8%) in the DP alone group were the documented grade 4 adverse events.